Tender detail
Open-house originator discount agreements 2026-14 for crizotinib
Summary
Participating health insurance funds intend to conclude non-exclusive discount agreements with suitable pharmaceutical companies for the active ingredient crizotinib. The open-house agreements run from 1 December 2026 for up to 24 months and end no later than 30 November 2028; they may end earlier if patent protection or market exclusivity expires.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.